The Effects of SDD on ICU Mortality

This can only be addressed in a cluster-randomized fashion, where as an infection control mechanism, SDD is applied to every eligible patient in the ICU. From 2014 to 2015, there was a series of attempts to fund this trial, which were only successful at that point in Australia from the National Health and Medical Research Council of Australia. And it was therefore necessary to move the sponsorship to the George Institute for Global Health in Sydney. With the endorsement of the Anzix Clinical Trials Group, this became an Australian trial, and presenting the results of the Australian trial.